Rhumbline Advisers Lineage Cell Therapeutics, Inc. Transaction History

Rhumbline Advisers

$104 Billion
Q1 2025

A detailed history of Rhumbline Advisers transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 201,447 shares of LCTX stock, worth $227,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares

201,447

Previous 201,447 -0.0%

Holding current value

$227,635

Previous $98,000 8.16%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 08, 2025	BUY	$0.45 - $0.72 $8,141 - $13,026	18,092 Added 9.87%	201,447 $98,000
Q4 2024 May 29, 2025	SELL	$0.5 - $0.95 $9,046 - $17,187	-18,092 Reduced 8.98%	183,355 $91,000
Q4 2024 Jan 30, 2025	SELL	$0.5 - $0.95 $1,771 - $3,365	-3,543 Reduced 1.9%	183,355 $91,000
Q3 2024 Nov 12, 2024	BUY	$0.8 - $1.12 $43,525 - $60,935	54,407 Added 41.06%	186,898 $170,000
Q2 2024 Aug 01, 2024	BUY	$0.89 - $1.47 $15,495 - $25,594	17,411 Added 15.13%	132,491 $132,000
Q1 2024 May 09, 2024	BUY	$0.86 - $1.48 $3,116 - $5,363	3,624 Added 3.25%	115,080 $170,000
Q4 2023 Feb 08, 2024	BUY	$0.91 - $1.35 $437 - $649	481 Added 0.43%	111,456 $121,000
Q3 2023 Nov 09, 2023	BUY	$1.16 - $1.53 $7,990 - $10,538	6,888 Added 6.62%	110,975 $130,000
Q2 2023 Aug 08, 2023	BUY	$1.26 - $1.53 $131,149 - $159,253	104,087 New	104,087 $146,000
Q2 2022 Aug 11, 2022	SELL	$1.12 - $1.61 $113,951 - $163,804	-101,742 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.21 - $2.48 $22,617 - $46,356	-18,692 Reduced 15.52%	101,742 $157,000
Q4 2021 Feb 10, 2022	BUY	$1.84 - $2.68 $3,148 - $4,585	1,711 Added 1.44%	120,434 $295,000
Q3 2021 Nov 12, 2021	BUY	$2.26 - $2.86 $14,030 - $17,754	6,208 Added 5.52%	118,723 $299,000
Q2 2021 Aug 05, 2021	BUY	$2.17 - $3.0 $244,157 - $337,545	112,515 New	112,515 $321,000
Q2 2020 Aug 13, 2020	SELL	$0.71 - $1.18 $128,044 - $212,805	-180,344 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$0.54 - $1.01 $77 - $144	143 Added 0.08%	180,344 $161,000
Q3 2019 Oct 23, 2019	BUY	$0.85 - $1.24 $153,170 - $223,449	180,201 New	180,201 $177,000

Others Institutions Holding LCTX

# of Institutions

139

Shares Held

108M

Call Options Held

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $192M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Lineage Cell Therapeutics, Inc. Transaction History